Approximately half of all AML adult patients lack clonal chromosome aberrations at diagnosis, and although this group has an intermediate prognosis, only 40% are long-term survivors. Therefore there is a clear need for specific molecular markers to improve prognosis, prediction of relapse and follow-up of AML patients.

Several studies have shown that in acute leukemia, level of WT1 transcript in mononuclear cells can be used to predict patient disease aggressiveness and determine patient response to treatment.

Establishing WT1 gene expression level at diagnosis, may therefore provide prognostic information on potential relapse following cytoreductive treatments. In addition, a prospective evaluation of WT1 gene expression in 133 paediatric and adult AML patients reports that monitoring WT1 levels may be a suitable alternative to specific fusion transcripts and provides a unique tool for the longitudinal follow-up of AML patients with a normal karyotype disease.

About WT1 and AML…

• WT1 is over-expressed in at least 75% of AML cases
• Quantification of WT1 over-expression can be used in cases lacking a leukemia-specific MRD marker
• This assay provides a precise measurement of disease response and quality of remission

See relevant publications

Ipsogen ProfileQuant® kits are unique quantitative molecular kits aiming at standardizing, detecting and quantifying profile gene transcripts in human cells.

ProfileQuant® Kit key points

Laboratory advantages

• Use peripheral blood specimen
• Quick test less than 3-hour turn-around time
• Sensitive quantitative measurement of the gene transcript

• 24 to 30 patient samples in duplicate
• Results in normalized copy numbers (NCN)
• Facilities and QMS compliant with ISO 13485 : 2003
• Multiplatform compatibility
• Standardized RQ-PCR procedures